GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (STU:C6K0) » Definitions » Current Deferred Revenue

Avalo Therapeutics (STU:C6K0) Current Deferred Revenue : €0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Avalo Therapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Avalo Therapeutics's current deferred revenue for the quarter that ended in Sep. 2024 was €0.00 Mil.

Avalo Therapeutics Current Deferred Revenue Historical Data

The historical data trend for Avalo Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Current Deferred Revenue Chart

Avalo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.08 -

Avalo Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Avalo Therapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalo Therapeutics Business Description

Traded in Other Exchanges
Address
540 Gaither Road, Suite 400, Rockville, MD, USA, 20850
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Headlines

No Headlines